Content
1. EXECUTIVE SUMMARY
2. INTRODUCTION
2.1 Definitions
2.2 Abbreviations
2.3 Market Positioning
2.4 UK Economy
2.5 Market Factors
3. MARKET SIZE AND TRENDS
3.1 Chapter Summary
3.2 Market Size
3.3 Market Segmentation
3.3.1 Prescription Medicines
3.3.2 OTC Medicines
3.4 Market Trends
3.4.1 Demographics
3.4.2 Expenditure
3.4.3 Distribution
3.4.4 Generics
3.4.5 Outsourcing
3.4.6 Parallel Trade
3.4.7 Herbal Medicines
4. SUPPLY SOURCES
4.1 Chapter Summary
4.2 Production
4.2.1 Overview
4.2.2 Segmentation
4.3 Imports
4.3.1 Overview
4.3.2 Segmentation
4.4 Exports
4.4.1 Overview
4.4.2 Segmentation
4.5 Trade Surplus/Deficit
5. INDUSTRY STRUCTURE
5.1 Chapter Summary
5.2 Industry Development
5.3 Structure by Employment
5.4 Structure by Turnover
5.5 Company Profiles
5.5.1 AstraZeneca
5.5.2 Bristol-Myers Squibb Pharmaceuticals
5.5.3 Celltech Group
5.5.4 Eli Lilly & Co
5.5.5 GE Healthcare
5.5.6 GlaxoSmithKline
5.5.7 Johnson & Johnson Medical
5.5.8 Merck Sharp & Dohme
5.5.9 Novartis UK
5.5.10 Pfizer
5.5.11 Pharmacia
5.5.12 Roche Products
5.5.13 Shire Pharmaceuticals Group
5.5.14 Unichem
5.5.15 3M Health Care
6. FORECAST
6.1 Chapter Summary
6.2 Market Size
6.3 Market Segmentation
6.4 Industry
7. FURTHER SOURCES & CONTACTS
7.1 Trade Associations
7.2 Trade Magazines
7.3 Trade Exhibitions
List of Tables
1: UK Apparent Consumption for Pharmaceutical Products, 2001-2005
2: UK Market for Pharmaceutical Products, 2001-2005
3: Segmentation of UK Apparent Consumption of Pharmaceutical Products, 2001-2005
4: Segmentation of the UK Market for Pharmaceutical Products, 2001-2005
5: Segmentation of the UK Market for Pharmaceutical Products, 2001-2005
6: Number of Prescription Items Dispensed in the UK Market, by Country, 2000-2004
7: Prescription Items Dispensed in England & Scotland, by Disease, 2004
8: UK Market for OTC Pharmaceutical Products and Top Branded Sellers, by Therapeutic Category, 2005
9: UK Population, by Age Group, 1981-2021
10: NHS Expenditure on Medicines in the UK, 2000-2004
11: NHS Pharmacies in England and Wales, 2000-2004
12: UK Production of Pharmaceutical Products, 2001-2005
13: Segmentation of the UK Production of Pharmaceutical Products, by Type,2001-2005
14: UK Imports of Pharmaceutical Products, 2001-2005
15: Segmentation of UK Imports of Pharmaceutical Products, by Type, 2001-2005
16: UK Exports of Pharmaceutical Products, 2001-2005
17: Segmentation of UK Exports of Pharmaceutical Products, by Type, 2001-2005
18: Analysis of the Changes in the Structure of the Basic Pharmaceuticals Manufacturing Industry,
2001-2005
19: Analysis of the Changes in the Structure of the Pharmaceutical Preparations
Manufacturing Industry, 2001-2005
20: Analysis of the Employment Structure of the Basic Pharmaceuticals
Manufacturing Industry, 2004 and 2005
21: Analysis of the Employment Structure of the Pharmaceutical Preparations
Manufacturing Industry, 2004 and 2005
22: Analysis of the Financial Structure of the Basic Pharmaceuticals
Manufacturing Sector, 2004 and 2005
23: Analysis of the Financial Structure of the Pharmaceutical Preparations
Manufacturing Sector, 2004 and 2005
24: Financial Analysis of AstraZeneca, 2000-2004
25: Key Financial Ratios for AstraZeneca, 2000-2004
26: Financial Analysis of Bristol-Myers Squibb Pharmaceuticals, 2000-2004
27: Key Financial Ratios for Bristol-Myers Squibb Pharmaceuticals, 2000-2004
28: Financial Analysis of Celltech Group, 1999-2003
29: Key Financial Ratios for Celltech Group, 1999-2003
30: Financial Analysis of Eli Lilly & Company, 1999-2003
31: Key Financial Ratios for Eli Lilly & Company, 1999-2003
32: Financial Analysis of GE Healthcare, 1999-2003
33: Key Financial Ratios for GE Healthcare, 1999-2003
34: Financial Analysis of GlaxoSmithKline, 2000-2004
35: Key Financial Ratios for GlaxoSmithKline, 2000-2004
36: Financial Analysis of Johnson & Johnson Medical, 1999-2003
37: Key Financial Ratios for Johnson & Johnson Medical, 1999-2003
38: Financial Analysis of Merck Sharp & Dohme, 1999-2003
39: Key Financial Ratios for Merck Sharp & Dome, 1999-2003
40: Financial Analysis of Novartis UK, 2000-2004
41: Key Financial Ratios for Novartis UK, 2000-2004
42: Financial Analysis of Pfizer, 2000-2004
43: Key Financial Ratios for Pfizer, 2000-2004
44: Financial Analysis of Pharmacia, 2000-2004
45: Key Financial Ratios for Pharmacia, 2000-2004
46: Financial Analysis of Roche Products, 2000-2004
47: Key Financial Ratios for Roche Products, 2000-2004
48: Financial Analysis of Shire Pharmaceuticals Group, 2000-2004
49: Key Financial Ratios for Shire Pharmaceuticals Group, 2000-2004
50: Financial Analysis of Unichem, 2000-2004
51: Key Financial Ratios for Unichem, 2000-2004
52: Financial Analysis of 3M Health Care, 2000-2004
53: Key Financial Ratios for 3M Health Care, 2000-2004
54: Forecast UK Apparent Consumption for Pharmaceutical Products, 2006-2010
55: Forecast UK Market for Pharmaceutical Products, 2006-2010
56: Forecast Segmentation of UK Apparent Consumption of Pharmaceutical
Products,
2006-2010
57: Forecast Segmentation of the UK Market for Pharmaceutical Products, 2006-
2010
List of Diagrams
1: World Pharmaceutical Market, by Retail Sales, 2005
2: Trade Surplus in the UK Pharmaceutical Products Industry, 2001-2005
|
